Détails du produit
Synonyms
PLAP
Source
Cynomolgus ALPP, His Tag (ALP-C52H3) is expressed from human 293 cells (HEK293). It contains AA Ile 21 - Asp 504 (Accession # XP_045223825.1).
Predicted N-terminus: Ile 21
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 54.6 kDa. The protein migrates as 65-70 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Shipping and Storage
This product is supplied and shipped on dry ice.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Cynomolgus ALPP, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA

Immobilized Cynomolgus ALPP, His Tag (Cat. No. ALP-C52H3) at 1 μg/mL (100 μL/well) can bind various dilution ratio of Anti-ALPP/ALPG/ALPI Polyclonal Antibody (QC tested).
Protocol
Bioactivity
Measured by its ability to cleave a fluorogenic substrate, 4-Methylumbelliferyl phosphate (4-MUP). The specific activity is >450 pmol/min/μg (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
Alkaline phosphatase, placental type
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
1 Détails
- Étape de développement la plus élevée:
Phase 2 Clinical



















